Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07605962
PHASE1/PHASE2

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

Sponsor: United Immunity, co., Ltd.

View on ClinicalTrials.gov

Summary

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.

Official title: A Phase I/II Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7/8 Agonist in Patients With Selected Locally Advanced and/or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2026-05-25

Completion Date

2031-03-31

Last Updated

2026-05-28

Healthy Volunteers

No

Conditions

Interventions

DRUG

UI-102

Specified dose on specified days

Locations (3)

NEXT Oncology

Dallas, Texas, United States

NEXT Oncology

Houston, Texas, United States

Next Oncology

San Antonio, Texas, United States